Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study will investigate the toxicity, safety and pharmacokinetics of pretargeted
radioimmunotherapy with anti-CEA x anti-hapten bispecific antibody TF2 and Lu-177-labeled
di-HSG-DOTA peptide IMP-288. Furthermore, the sensitivity of pretargeted imaging with
In-111-labeled IMP-288 as compared to standard methods of tumor detection, and the
preliminary efficacy of the therapy.